Akari Kamitani

Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings

T. Sonoyama, S. Iwata, S. Omoto, 2022, Vaccine.

Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study

M. Shinkai, M. Shinoda, T. Sonoyama, 2022, Vaccine.